- Other Name
- NCI
- Sponsors Type
- Federal/National
- Country
- United States
- Grant Types
- Fellowship/Scholarship/Dissertation Internship/Work-study Research Project Training/Course Travel Workshop/Conference Post-doctoral Collaboration/Cooperative Agreement Equipment/Facility/Organization Artistic/Exhibit/Collection Publishing/Editorial Other
- Topics
- cancer research translational cancer research health disparities cancer prevention cancer therapeutics cancer biology clinical trials data sharing clinical oncology cancer cell biology
Contact Info
- Phone
- (1-800-422-6237)
- NCIinfo@nih.gov
Last modified on 2025-11-18 01:06:31
Description
The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training.
**NCI Mission**
NCI leads, conducts, and supports cancer research across the nation to advance scientific knowledge and help all people live longer, healthier lives.
Sponsor Relationship
National Cancer Institute is a part of:
The following sponsors are parts of National Cancer Institute:
Most Recent Grants from This Sponsors
**Funding Opportunity Number:** PAR-28-042
Funding Opportunity Purpose
The purpose of the...
Added on 2026-11-03
**Funding Opportunity Number:** PAR-28-063
**Funding Opportunity Purpose**
Through this notice...
Added on 2026-11-03
Funding Opportunity Number: PA-26-002
**Section I. Notice of Funding Opportunity Description**...
Added on 2026-10-22
Funding Opportunity Number: RFA-LM-28-001
**Section I. Funding Opportunity Description** ...
Added on 2026-10-16
Deadline Approaching Grants
Notice Number: NOT-CA-24-016
**Purpose**
Through this Notice of Special Interest (NOSI) on...
Deadline on 2026-11-17
Funding Opportunity Number: PAR-25-371
**Section I. Notice of Funding Opportunity Description** ...
Deadline on 2026-11-18
Funding Opportunity Number: PAR-25-369
**Section I. Notice of Funding Opportunity Description**...
Deadline on 2026-11-18
Funding Opportunity Number: PA-27-061
**Section I. Notice of Funding Opportunity Description**...
Deadline on 2026-11-20